Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.7803 EUR
−7.61 M EUR
0.00 EUR
4.66 M
About Monopar Therapeutics Inc
Sector
Industry
CEO
Chandler Drew Robinson
Website
Headquarters
Wilmette
Founded
2014
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Monopar Therapeutics Inc stocks are traded under the ticker A40JML.
A40JML stock hasn't changed in a week, the last month showed zero change in price, over the last year Monopar Therapeutics Inc has showed a 13.53% increase.
We've gathered analysts' opinions on Monopar Therapeutics Inc future price: according to them, A40JML price has a max estimate of 88.20 EUR and a min estimate of 21.32 EUR. Watch A40JML chart and read a more detailed Monopar Therapeutics Inc stock forecast: see what analysts think of Monopar Therapeutics Inc and suggest that you do with its stocks.
A40JML stock is 13.53% volatile and has beta coefficient of 3.28. Track Monopar Therapeutics Inc stock price on the chart and check out the list of the most volatile stocks — is Monopar Therapeutics Inc there?
Yes, you can track Monopar Therapeutics Inc financials in yearly and quarterly reports right on TradingView.
Monopar Therapeutics Inc is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
A40JML earnings for the last quarter are −0.33 EUR per share, whereas the estimation was −0.89 EUR resulting in a 62.81% surprise. The estimated earnings for the next quarter are −0.34 EUR per share. See more details about Monopar Therapeutics Inc earnings.
Monopar Therapeutics Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
A40JML net income for the last quarter is −1.17 M EUR, while the quarter before that showed −1.60 M EUR of net income which accounts for 26.85% change. Track more Monopar Therapeutics Inc financial stats to get the full picture.
No, A40JML doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 10.00 employees. See our rating of the largest employees — is Monopar Therapeutics Inc on this list?
Like other stocks, A40JML shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monopar Therapeutics Inc stock right from TradingView charts — choose your broker and connect to your account.